This CGM will track your body's response - Could personalised glucose data inform your body’s metabolism and performance?

BofA Securities maintained a Buy rating on DexCom (NASDAQ:DXCM) shares, with a steady price target of $90.00. The firm's analysts suggest the current market movement presents an appealing opportunity ...

Retirement Systems of Alabama lowered its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 2.5% in the 4th quarter, ...

The ancient Greek philosopher and polymath Aristotle once concluded that the human heart is tri-chambered and that it was the ...

Diabetes can lead to serious complications when not properly managed. Over time, high blood sugar levels can damage blood ...

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.

These days, many devices are programmed through apps on patients’ phones. But the FDA warns that certain phone settings, such ...

Senseonics Holdings, Inc.’s SENS share price has surged by 13.29%, which has investors questioning if this is right time to ...

Gonzaga University and the UW School of Medicine hosted Irl Hirsch to lecture about the future of glucose monitoring.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...